DURHAM, NC - Researchers for the first time have shown how engineered stem cells can be used to deliver antibodies superior to those currently available for protecting against infectious diseases and biological warfare. The study appears in the August issue of STEM CELLS Translational Medicine.
You are here
Press Releases from AlphaMed Press
Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.
DURHAM, NC - The medical world may be one step closer to an affordable, effective therapeutic vaccine for hepatitis C virus (HCV), according to a new study appearing in the latest issue of STEM CELLS Translational Medicine. The study, by scientists at Second Military Medical University in Shanghai, showed how exosomes secreted from umbilical mesenchymal stem cells (uMSC) efficiently suppressed HCV infection.
Chronic hepatitis C is a serious disease that can result in long-term health problems. Worldwide, 700,000 people die each year from HCV-related liver diseases, according to the World Health Organization. While newly developed antiviral medicines could cure approximately 90 percent of those with HCV infection, access to diagnosis and treatment is limited and there is currently no vaccine to prevent it.
DURHAM, NC - A new study published in STEM CELLS Translational Medicine (SCTM) by Badner et al shows how a minimally invasive stem cell treatment in rats can reduce secondary damage in traumatic spinal cord injury (SCI). While similar studies have also demonstrated the promise of stem cells as a therapy for SCI, what makes this one different is the type of stem cell used. For the first time, researchers evaluated whether a brain-derived stromal cell would be better suited to target the acute phase of SCI than cells derived from other tissue sources. The answer was yes.
DURHAM, NC - In a new case report published today in STEM CELLS Translational Medicine, doctors at Odense University Hospital in Denmark detail how a patient who developed lymphedema after being treated for breast cancer benefitted from an injection of stem cells derived from adipose (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment.
Lymphedema refers to the swelling that generally occurs in an arm or leg – or both – after lymph nodes have either been surgically removed (lymphadenectomy) or damaged by radiation during cancer treatment, particularly for breast cancer. Some patients’ bodies are able to accommodate for the missing or damaged nodes, but in others this causes a blockage in the lymphatic system, which in turn leads to a buildup of waste and fluid.
DURHAM, NC - A new study appearing in STEM CELLS Translational Medicine (SCTM) indicates that a single low dose of a patient’s own stem cells might offer relief from osteoarthritis of the knee.
Osteoarthritis (OA) is the most common chronic condition of the joints, resulting from the cartilage or cushion between the joints breaking down. This leads to pain, stiffness and swelling. OA is on the rise in the western world, in part because of the aging population and also because of obesity, which strains the joints by increasing the load they carry. Any joint in the body may be affected by OA, but it is particularly common in the knee.
DURHAM, NC - Treatment for full-term babies born with hypoxic-ischemic– brain damage due to blood and oxygen deprivation injuries is currently limited to therapeutic cooling to improve outcomes. There is no treatment for pre-term babies; however, a new study appearing in the latest issue of STEM CELLS Translational Medicine may lead to therapies that repair damage from hypoxia-ischemia.
Durham, NC – A new study in STEM CELLS Translational Medicine offers people with genetic hearing loss the promise of a new therapy that just might outperform artificial cochlear implants.
Implants currently are the most effective way to treat sensorineural hearing loss, a type of hereditary hearing loss caused by genetic mutations in the hair cells — the sensory receptors of the auditory system, found in the inner ear (the cochlea). A cochlear implant helps transfer sound to the patient’s hearing nerves and enables them to hear. But many researchers believe that stem cells could offer a more comprehensive and better fix for this problem.
Durham, NC – A study recently published in STEM CELLS Translational Medicine points the way to a new, potentially restorative treatment for age-related or type II osteoporosis. When a single dose of a certain type of stem cell, called mesenchymal stromal cells (MSCs), was injected into mice with the disease, long-term bone engraftment and quality bone growth resulted. As an added benefit, the cells protected existing bone from damage.
Durham, NC – A new type of engineered stem cell could transform how Alzheimer's disease (AD) is treated and perhaps even stop the disease in its tracks. In a study recently published in STEM CELLS Translational Medicine, a team of University of Michigan researchers describe how they revved up the levels of a protein called IGF-I in a line of neuronal stem cells (NSCs), which resulted in the NSCs producing brain cells that were both resistant to AD and capable of restoring AD-ravaged cells to normal.
Durham, NC – A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method for turning fibroblasts — the most common cells in connective tissue — into cardiac progenitor cells (CPCs). The results could lead to a much-needed new source of cells for regenerating the heart. Equally exciting is that the technology also converts the fibroblasts directly to CPCs, skipping an in-between and significantly speeding up the process.